Efficacy and Tolerance of Pegaspargase-Based Chemotherapy in Patients with Nasal-Type Extranodal NK/T-Cell Lymphoma: a Pilot Study

Wen, Jing-Yun; Li, Mai; Li, Xing; Chen, Jie; Lin, Qu; Ma, Xiao-Kun; Dong, Min; Wei, Li; Chen, Zhan-Hong; Wu, Xiang-Yuan

추천

검색

자료유형: 학술저널

저자정보: Wen, Jing-Yun (Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-Sen University) Li, Mai (Department of Biotechnology, Guangdong Food and Drug Vocational College) Li, Xing (Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-Sen University) Chen, Jie (Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-Sen University) Lin, Qu (Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-Sen University) Ma, Xiao-Kun (Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-Sen University) Dong, Min (Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-Sen University) Wei, Li (Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-Sen University) Chen, Zhan-Hong (Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-Sen University) Wu, Xiang-Yuan (Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-Sen University)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제15권 제15호

발행연도: 2014.1

수록면: 6,275 - 6,281 (7page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Nasal-type extranodal natural killer (NK)/T-cell lymphoma (ENKL) is a highly invasive cancer with a poor prognosis. More effective and safer treatment regimens for ENKL are needed. Pegaspargase (PEG-Asp) has a similar mechanism of action to L-asparaginase (L-Asp), but presents lower antigenicity. The aim of the present research was to evaluate the safety profile and the latent efficacy of a PEG-Asp-based treatment regimen in patients with ENKL. Data collected from 20 patients with histologically confirmed ENKL, admitted to the Third Affiliated Hospital of Sun Yat-Sen University from January 2009 to August 2013, were included in the study. All patients received $2500IU/m^2$/IM PEG-Asp on day 1 of every 21-day treatment cycle. Patients received combination chemotherapy with CHOP (n=5), EPOCH (n=7), GEMOX (n=7) or CHOP with bleomycin (n=1). After 2-5 treatment cycles (median, 4 cycles) of PEG-Asp-based chemotherapy, five patients (25%) showed a complete response (CR), and the overall response rate (ORR) was 60%. Grade 3/4 neutropenia occurred in fourteen patients (70%). Grade 3 alanine aminotransferase (ALT) elevation was observed in two. Grade 1-2 non-hematological toxicity consisted of activated partial thromboplastin time (APTT) elongation (n=9), hypofibrinogenemia (n=6), hypoproteinemia (n=17), hyperglycemia (n=3), and nausea (n=6). No allergic reactions were detected. No treatment related death was reported. Our results suggested that PEG-Asp-based chemotherapy presented an acceptable tolerance and a potential short-term outcome in patients with nasal-type ENKL.

#Nasal #type extranodal NK/T #cell lymphoma #pegaspargase #response rate #safety #L-asparaginase

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요